CNS research sees some breakthroughs

June 23, 2015 Guest Contributor

Guest post by Hamish McDougall, Reporter at BioPharm Insight

BioPharm Insight’s (BPI) editorial neurology report highlights physicians’ renewed interest in amyloid reducing therapies for Alzheimer’s disease modification, the most notable from Biogen in Phase Ib. Meanwhile, multiple symptomatic AD treatments targeting cognitive deficits, psychosis and agitation/aggression are still being supported by physicians given the stark unmet need.

In Parkinson’s disease, several symptomatic drug approvals are expected in the next year, while earlier stage disease modifying therapies targeting alpha-synuclein will likely face trial challenges despite growing evidence supporting this approach. Elsewhere in the movement disorders space, Phase II-III VMAT2 inhibitors for tardive dyskinesia herald a promising future, while in muscular dystrophy, all eyes are on exon skipping drugs and how regulators may react to mixed data.

BioPharm InsightBPI_vertical’s Neurology Report is a compilation of investigative news articles covering drug development across the therapeutic area, please click here for the full report. To request a free trial with BPI, please click here.


Meet Biogen and other potential partners at BioPharm America™  in Boston this September.

 

 

Read more...

Previous Article
Reasons why Boston is an ideal biotech hub for forging alliances
Reasons why Boston is an ideal biotech hub for forging alliances

BioPharm America™ 2015 plays an essential role in forging vital partnerships across the life science ecosys...

Next Article
Aisling Capital’s Dennis Purcell on Boston, serial entrepreneurs, and leveraging the life science ecosystem
Aisling Capital’s Dennis Purcell on Boston, serial entrepreneurs, and leveraging the life science ecosystem

No other industry relies on cross-pollinating collaborations that span the ecosystem like biotech. From sta...